Hangzhou TianMuShan Pharmaceutical EnterpriseLtd Valuation

Is 600671 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600671 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 600671's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 600671's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600671?

Key metric: As 600671 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 600671. This is calculated by dividing 600671's market cap by their current revenue.
What is 600671's PS Ratio?
PS Ratio	6.9x
Sales	CN¥160.35m
Market Cap	CN¥1.09b

600671 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	7.5x
Enterprise Value/EBITDA	-186.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 600671's PS Ratio compare to its peers?

The above table shows the PS ratio for 600671 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.4x
002872 Tiansheng Pharmaceutical Group	2.6x	n/a	CN¥1.5b
300871 Hvsen Biotechnology	1.7x	20.0%	CN¥1.9b
603139 Shaanxi Kanghui Pharmaceutical	2.5x	n/a	CN¥1.6b
301065 Zhejiang Benli Technology	3x	n/a	CN¥2.1b
600671 Hangzhou TianMuShan Pharmaceutical EnterpriseLtd	6.9x	n/a	CN¥1.1b

Price-To-Sales vs Peers: 600671 is expensive based on its Price-To-Sales Ratio (6.9x) compared to the peer average (2.4x).

Price to Sales Ratio vs Industry

How does 600671's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
600664 Harbin Pharmaceutical Group	0.6x	n/a	US$1.28b
000411 Zhejiang Int'l GroupLtd	0.2x	n/a	US$778.04m
000153 Anhui Fengyuan Pharmaceutical	0.7x	n/a	US$410.83m
600781 FUREN Group PharmaceuticalLtd	0.3x	n/a	US$66.91m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 600671 is expensive based on its Price-To-Sales Ratio (6.9x) compared to the CN Pharmaceuticals industry average (3.6x).

Price to Sales Ratio vs Fair Ratio

What is 600671's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600671 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	6.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 600671's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.31

-1.4%

-24.4%

Sichuan Kelun Pharmaceutical

CN¥48.4b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.05

3.7%

7.9%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥57.18

-1.8%

13.3%